

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

Claims 1-19 (Canceled)

Claim 20 (Currently Amended) A method for administering a biologically active agent, the method comprising:

injecting a formulation comprising:

- (a) an injection vehicle comprising hyaluronic acid dissolved in a physiological buffer at a concentration of about 0.01 to about 3 percent weight per volume; and
- (b) particles comprising:
  - (i) a first component that is the biologically active agent; and
  - (ii) a second component that is a biocompatible polymeric matrix.

Claim 21 (Canceled)

Claim 22 (Currently Amended) An injectable formulation, comprising:

- (a) an injection vehicle comprising hyaluronic acid dissolved in a physiological buffer at a concentration of about 0.01 to about 3 percent weight by volume; and
- (b) particles, comprising:
  - (i) a first component that is a biologically active agent, and
  - (ii) a second component that is a biocompatible polymeric matrix.

Claim 23 (Previously Presented) The injectable formulation of claim 22, wherein the physiological buffer comprises physiological saline.

Claim 24 (Canceled)

Claim 25 (Previously Presented) The injectable formulation of claim 22, wherein the polymeric matrix comprises a blocked polymer.

Claim 26 (Previously Presented) The injectable formulation of claim 22, wherein the polymeric matrix comprises an unblocked polymer.

Claim 27 (Previously Presented) The injectable formulation of claim 22, wherein the polymer is a poly(lactide-co-glycolide).

Claim 28 (Previously Presented) The injectable formulation of claim 22, wherein the biologically active agent is a polypeptide.

Claim 29 (Previously Presented) The injectable formulation of claim 28, wherein the polypeptide is selected from the group consisting of a growth hormone, a hepatocyte growth factor (HGF), a vascular endothelial growth factor (VEGF), a glucagon-like peptide I (GLP-I), a nerve growth factor, an insulin-like growth factor, and an antibody.

Claim 30 (Previously Presented) The injectable formulation of claim 22, wherein the concentration of the polymeric matrix is about 1 mg/mL to about 500 mg/mL of formulation.

Claim 31 (Previously Presented) The injectable formulation of claim 30, wherein the concentration of the polymeric matrix is about 1 mg/mL to about 300 mg/mL of formulation.

Claim 32 (Canceled)

Claim 33 (Previously Presented) The injectable formulation of claim 22, wherein the hyaluronic acid is N-acylurea modified hyaluronic acid.

Claim 34 (Previously Presented) The injectable formulation of claim 22, wherein the hyaluronic acid is sodium hyaluronate.

Claim 35 (Canceled)

Claim 36 (Previously Presented) The injectable formulation of claim 29, wherein the polypeptide is an anti-vascular endothelial growth factor Fab (anti-VEGF Fab).

Claim 37 (Canceled)

Claim 38 (Canceled)

Claim 39 (Canceled)

Claim 40 (Previously Presented) The method of claim 20, wherein the concentration of hyaluronic acid is about 0.01 to about 1 percent weight per volume.

Claim 41 (Previously Presented) The method of claim 40, wherein the concentration of hyaluronic acid is about 0.01 to about 0.8 percent weight per volume.

Claim 42 (Previously Presented) The injectable formulation of claim 22, wherein the concentration of hyaluronic acid is about 0.01 to about 1 percent weight per volume.

Claim 43 (Previously Presented) The injectable formulation of claim 42, wherein the concentration of hyaluronic acid is about 0.01 to about 0.8 percent weight per volume.

Claim 44 (Canceled)